BLASINGLE-USEVIALPriority Review
Approved
Jun 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
PERJETA (pertuzumab) by Roche is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2012.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERJETA (pertuzumab) is a monoclonal antibody developed by Roche that targets HER2/neu receptors, a key driver of aggressive breast cancer growth. It works by blocking HER2 signaling through a distinct mechanism from trastuzumab (Herceptin), complementing rather than competing with existing HER2-directed therapies. PERJETA is indicated for HER2-positive breast cancer and is typically used in combination with trastuzumab and chemotherapy. It represents a foundational dual HER2-blockade approach that has become standard of care in HER2-positive early and metastatic breast cancer.
$0.0BPart D
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Started May 2026
60 enrolled
HER2-positive Recurrent or Metastatic Breast Cancer
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Started Apr 2026
596 enrolled
HER2-positive Breast Cancer
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Started Nov 2025
63 enrolled
Biliary Tract Cancer (BTC)First-line Therapy
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Started Jun 2025
642 enrolled
Breast Cancer
Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer
Started Jun 2025
24 enrolled
Rectal CancerHER2-positive
Worked on PERJETA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.